Around 500 swine veterinarians attended Ceva’s symposium during the 8th International Pig Veterinary Society congress in Wuhan, China. The symposium was dedicated to Porcine Circovirus Disease, a topic which has high relevance for the swine industry in the whole Asian region.
The program was kicked off by Professor Mathias Ritzmann from the University of Munich (Germany). Professor Ritzmann presented a general overview about the disease, and the benefits of vaccination. Afterwards, he talked about the emerging new genotypes of PCV2, and discussed the importance of high levels of maternal antibodies in piglets when determining the ideal vaccination scheme.
The second speaker was Wouter van Herten, swine veterinarian in one of the largest swine veterinary clinics in the the Netherlands. Dr. van Herten shared his experiences of implementing porcine circovirus vaccination in modern European herds. Among other topics, he showed technical improvements in his clients’ farms when implementing piglet vaccination protocols in herds affected by subclinical PCVD. The use of Circovac led to an increase in daily growth, a reduction in mortality and an improvement in carcass quality at the slaughterhouse.
Afterwards Dr. Han Smits, Technical Director at Ceva Phylaxia in Budapest (Hungary), highlighted the benefits of using whole-virus technology in PCV2 vaccines. Different from its competitors, Circovac provides immunity against both ORF-1 and ORF-2 of the PCV2 virus. Dr. Smits also shared the results of a recent study showing cross protection of Circovac against infection with the emerging PCV2d strain. Lastly, he summarised the many field studies available for Circovac, and highlighted the improvement farmers can expect when applying the vaccine in piglets in their herds: more growth, less mortality, a better feed conversion ratio and less treatments with antibiotics.